Literature DB >> 27009099

Opioids and Opioid Maintenance Therapies: Their Impact on Monocyte-Mediated HIV Neuropathogenesis.

Matias Jaureguiberry-Bravo, Rebecca Wilson, Loreto Carvallo, Joan W Berman1.   

Abstract

BACKGROUND: HIV-1 enters the CNS within two weeks after peripheral infection and results in chronic neuroinflammation that leads to HIV associated neurocognitive disorders (HAND) in more than 50% of infected people. HIV enters the CNS by transmigration of infected monocytes across the blood brain barrier. Intravenous drug abuse is a major risk factor for HIV-1 infection, and opioids have been shown to alter the progression and severity of HAND. Methadone and buprenorphine are opioid derivates that are used as opioid maintenance therapies. They are commonly used to treat opioid dependency in HIV infected substance abusers, but their effects on monocyte migration relevant to the development of cognitive impairment are not well characterized.
CONCLUSION: Here, we will discuss the effects of opioids and opioid maintenance therapies on the inflammatory functions of monocytes and macrophages that are related to the development of neuroinflammation in the context of HIV infection.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27009099      PMCID: PMC5487025          DOI: 10.2174/1570162x14666160324124132

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  142 in total

Review 1.  The chemokine system in neuroinflammation: an update.

Authors:  R M Ransohoff
Journal:  J Infect Dis       Date:  2002-12-01       Impact factor: 5.226

Review 2.  Role of buprenorphine in the management of heroin addiction.

Authors:  Soojin Sung; John M Conry
Journal:  Ann Pharmacother       Date:  2006-01-24       Impact factor: 3.154

Review 3.  Role of mu-opioids as cofactors in human immunodeficiency virus type 1 disease progression and neuropathogenesis.

Authors:  Anupam Banerjee; Marianne Strazza; Brian Wigdahl; Vanessa Pirrone; Olimpia Meucci; Michael R Nonnemacher
Journal:  J Neurovirol       Date:  2011-07-07       Impact factor: 2.643

4.  Suppression of human peripheral blood mononuclear cell function by methadone and morphine.

Authors:  P K Peterson; G Gekker; C Brummitt; P Pentel; M Bullock; M Simpson; J Hitt; B Sharp
Journal:  J Infect Dis       Date:  1989-03       Impact factor: 5.226

5.  No detrimental effect from chronic exposure to buprenorphine on corticosteroid-binding globulin and corticosensitive immune parameters.

Authors:  M D'Elia; J Patenaude; C Hamelin; D R Garrel; J Bernier
Journal:  Clin Immunol       Date:  2003-11       Impact factor: 3.969

Review 6.  Opiate inhibition of chemokine-induced chemotaxis.

Authors:  M C Grimm; A Ben-Baruch; D D Taub; O M Howard; J M Wang; J J Oppenheim
Journal:  Ann N Y Acad Sci       Date:  1998-05-01       Impact factor: 5.691

7.  Methadone ameliorates multiple-low-dose streptozotocin-induced type 1 diabetes in mice.

Authors:  K Amirshahrokhi; A R Dehpour; J Hadjati; M Sotoudeh; M Ghazi-Khansari
Journal:  Toxicol Appl Pharmacol       Date:  2008-07-11       Impact factor: 4.219

8.  Mu-opioid modulation of HIV-1 coreceptor expression and HIV-1 replication.

Authors:  Amber D Steele; Earl E Henderson; Thomas J Rogers
Journal:  Virology       Date:  2003-04-25       Impact factor: 3.616

9.  The types of drugs used by HIV-infected injection drug users in a multistate surveillance project: implications for intervention.

Authors:  T Diaz; S Y Chu; R H Byers; B S Hersh; L Conti; C A Rietmeijer; E Mokotoff; S A Fann; D Boyd; L Iglesias
Journal:  Am J Public Health       Date:  1994-12       Impact factor: 9.308

10.  The alterations of immunological reactivity in heroin addicts and their normalization in patients maintained on methadone.

Authors:  A Zajícová; H Wilczek; V Holán
Journal:  Folia Biol (Praha)       Date:  2004       Impact factor: 0.906

View more
  7 in total

1.  Frontline Science: Buprenorphine decreases CCL2-mediated migration of CD14+ CD16+ monocytes.

Authors:  Matias Jaureguiberry-Bravo; Lillie Lopez; Joan W Berman
Journal:  J Leukoc Biol       Date:  2018-05-23       Impact factor: 4.962

2.  Accelerated and Premature Aging Characterizing Regional Cortical Volume Loss in Human Immunodeficiency Virus Infection: Contributions From Alcohol, Substance Use, and Hepatitis C Coinfection.

Authors:  Adolf Pfefferbaum; Natalie M Zahr; Stephanie A Sassoon; Dongjin Kwon; Kilian M Pohl; Edith V Sullivan
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2018-07-04

3.  Cell-type specific differences in antiretroviral penetration and the effects of HIV-1 Tat and morphine among primary human brain endothelial cells, astrocytes, pericytes, and microglia.

Authors:  Sulay H Patel; Omnia A Ismaiel; William R Mylott; Moucun Yuan; Joseph L McClay; Jason J Paris; Kurt F Hauser; MaryPeace McRae
Journal:  Neurosci Lett       Date:  2019-09-03       Impact factor: 3.046

4.  Treatment with buprenorphine prior to EcoHIV infection of mice prevents the development of neurocognitive impairment.

Authors:  Matias Jaureguiberry-Bravo; Jennifer Kelschenbach; Aniella Murphy; Loreto Carvallo; Eran Hadas; Lydia Tesfa; Travis M Scott; Monica Rivera-Mindt; Chinazo O Cunningham; Julia H Arnsten; David J Volsky; Joan W Berman
Journal:  J Leukoc Biol       Date:  2020-06-24       Impact factor: 4.962

Review 5.  The Opioid Epidemic: Impact on Inflammation and Cardiovascular Disease Risk in HIV.

Authors:  Corrilynn O Hileman; Grace A McComsey
Journal:  Curr HIV/AIDS Rep       Date:  2019-10       Impact factor: 5.495

6.  Chronic morphine administration differentially modulates viral reservoirs in SIVmac251 infected rhesus macaque model.

Authors:  Arpan Acharya; Omalla A Olwenyi; Michellie Thurman; Kabita Pandey; Brenda M Morsey; Benjamin Lamberty; Natasha Ferguson; Shannon Callen; Qiu Fang; Shilpa J Buch; Howard S Fox; Siddappa N Byrareddy
Journal:  J Virol       Date:  2020-12-16       Impact factor: 5.103

Review 7.  Opioid and neuroHIV Comorbidity - Current and Future Perspectives.

Authors:  Sylvia Fitting; MaryPeace McRae; Kurt F Hauser
Journal:  J Neuroimmune Pharmacol       Date:  2020-09-02       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.